Neuroendocrine Unit

Physician Photo

Steven Kyle Grinspoon, MD

Director, MGH Program in Nutritional Metabolism

Co-Director, Nutrition Obesity Research Center, Harvard

  • Phone: 617-724-9109
Department of Medicine
Clinical Interests
Pituitary disease
Endocrine manifestations of AIDS
Boston: Massachusetts General Hospital
Medical Education
MD, University of Rochester School of Medicine and Dentistry
Residency, New York Presbyterian Hospital
Fellowship, Massachusetts General Hospital
Board Certifications
Endocrinology, Diabetes & Metabolism, American Board of Internal Medicine
Patient Age Group
Accepting New Patients
Accepting New Patients

BiographySteven K. Grinspoon, MD is a clinician in the Neuroendocrine Clinical Center and a faculty member in the Neuroendocrine Unit at the Massachusetts General Hospital, and a Professor of Medicine at Harvard Medical School.  He is a clinical researcher who studies hypothalamic control of body weight and fat distribution in obesity and lipodystrophy with a focus on the metabolic and cardiovascular consequences of visceral fat accumulation.  Awards in recognition of his work have included selection to the American Society for Clinical Investigation, the Association of American Physicians and the 2014 Daniel Ahrens Award for Translational Science Research by the Association of Clinical and Translational Science.  He is the author of more than 190 peer-reviewed publications and serves as the Co-Director of the Nutrition Obesity Research Center at Harvard and as the Director of the MGH Program in Nutritional Metabolism.

ResearchDr. Grinspoon is a clinical researcher who studies the development of novel neuroendocrine strategies to reduce cardiovascular and metabolic risk associated with excess visceral fat, with a focus on the use of growth hormone releasing hormone (GHRH) to increase endogenous pulsatile GH, and selectively reduce visceral fat. His research interests include metabolic consequences of visceral fat accumulation in lipodystrophy and obesity.

PublicationsHadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S.  Effects of Rosiglitazone on Metabolic Indices and Fat in HIV Lipodystrophy: A Randomized Controlled Trial.  Ann Intern Med. 2004; 140: 786 - 794.

Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger B, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic Effects of a Growth Hormone-Releasing Factor in HIV Patients. N Engl J Med 2007; 357:2359-70.

Lo J, You SM, Canavan B, Liebau J, Beltrani G, Koutkia P, Hemphill L, Lee H, Grinspoon S. Low Dose Physiologic Growth Hormone in HIV Patients with Abdominal Fat Accumulation: A Randomized Controlled Trial. JAMA. 2008; 300:509-519. PMCID: PMC2532757

Subramanian S*, Tawakol A*, Burdo T, Abbara S, Wei, J, Vijayakumar J, Corsini E, Abdelbarky A, Zanni M, Hoffman U, Williams K, Lo J?, Grinspoon S?. Arterial Inflammation in HIV-Infected Patients. JAMA 2012. Jul 25;308(4):379-86. PMCID: PMC3724172

Stanley TL, Feldpausch M, Oh J, Branch K, Lee H, Torriani M, Grinspoon SK. Effects of Tesamorelin on Visceral Fat and Liver Fat in HIV-infected Patients with Abdominal Fat Accumulation: A Randomized Clinical Trial. JAMA. 2014 Jul 23-30;312(4):380-9. PMID:25038357

Diabetes drug halts atherosclerosis progression in HIV-infected patients

Treatment with the common diabetes drug metformin appears to prevent progression of coronary atherosclerosis in patients infected with HIV.

Increased cardiovascular risk in HIV-infected patients may relate to arterial inflammation

The elevated risk of cardiovascular disease seen in patients infected with HIV appears to be associated with increased inflammation within the arteries, according to a study in a special issue of JAMA published in conjunction with the International AIDS Conference.

Differences in plaque composition, immune activation may explain elevated cardiovascular risk in HIV-infected women

An MGH research team has discovered a possible mechanism behind the elevated risk of cardiovascular disease in women infected with HIV, a risk even higher than that of HIV-infected men.

Drug that reduces abdominal fat in HIV patients also may reduce fat in liver

The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients.

Can statin treatment cut cardiovascular risk in HIV-infected patients?

A nationwide study based at MGH will investigate, for the first time, whether treatment with a statin drug can reduce the elevated risk of cardiovascular disease in individuals infected with the human immunodeficiency virus.

Trial of statin therapy to reduce HIV-associated cardiovascular risk open for enrollment

The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at the MGH, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand.

Program in Nutritional Metabolism
55 Fruit Street
Boston, MA 02114-2696

Phone: 617-724-9109
Fax: 617-724-8998

Neuroendocrine Clinical Center
Zero Emerson Place
Boston, MA 02114-2217

Phone: 617-726-7948
Phone 2: 617-726-6813
Fax: 617-726-1241